Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franck Bonnetain

Showing results (71-80 of 161) with videos related to

Pageof 17
Sort By:
World Journal of Gastroenterology|September 13, 2012
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-saltsCindy Neuzillet, Olivia Hentic, Benoît Rousseau, et al.
Health and Quality of Life Outcomes|December 5, 2016
Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over timeAhmad Ousmen, Thierry Conroy, Francis Guillemin, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2013
Platinum-sensitivity in metastatic colorectal cancer: towards a definitionBenoist Chibaudel, Christophe Tournigand, Franck Bonnetain, et al.
Gut|October 20, 2009
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancerBoris Guiu, Jean Michel Petit, Franck Bonnetain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trialChristophe Tournigand, Thierry André, Franck Bonnetain, et al.
Plos One|May 16, 2014
Impact of response shift on time to deterioration in quality of life scores in breast cancer patientsZeinab Hamidou, Tienhan S Dabakuyo-Yonli, Francis Guillemin, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational studyIsabelle Monnet, Clarisse Audigier-Valette, Nicolas Girard, et al.
Plos One|June 17, 2016
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III TrialZeinab Hamidou, Benoist Chibaudel, Mohamed Hebbar, et al.
The Oncologist|August 24, 2011
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR studyBenoist Chibaudel, Franck Bonnetain, Christophe Tournigand, et al.
Health and Quality of Life Outcomes|March 11, 2014
Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality of life study in breast cancer patientsAmélie Anota, Caroline Bascoul-Mollevi, Thierry Conroy, et al.
Pageof 17

Showing results (71-80 of 161) with videos related to

Sort By:
Pageof 17
World Journal of Gastroenterology|September 13, 2012
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-saltsCindy Neuzillet, Olivia Hentic, Benoît Rousseau, et al.
Health and Quality of Life Outcomes|December 5, 2016
Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over timeAhmad Ousmen, Thierry Conroy, Francis Guillemin, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2013
Platinum-sensitivity in metastatic colorectal cancer: towards a definitionBenoist Chibaudel, Christophe Tournigand, Franck Bonnetain, et al.
Gut|October 20, 2009
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancerBoris Guiu, Jean Michel Petit, Franck Bonnetain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2012
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trialChristophe Tournigand, Thierry André, Franck Bonnetain, et al.
Plos One|May 16, 2014
Impact of response shift on time to deterioration in quality of life scores in breast cancer patientsZeinab Hamidou, Tienhan S Dabakuyo-Yonli, Francis Guillemin, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational studyIsabelle Monnet, Clarisse Audigier-Valette, Nicolas Girard, et al.
Plos One|June 17, 2016
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III TrialZeinab Hamidou, Benoist Chibaudel, Mohamed Hebbar, et al.
The Oncologist|August 24, 2011
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR studyBenoist Chibaudel, Franck Bonnetain, Christophe Tournigand, et al.
Health and Quality of Life Outcomes|March 11, 2014
Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality of life study in breast cancer patientsAmélie Anota, Caroline Bascoul-Mollevi, Thierry Conroy, et al.
Pageof 17